Double-Stranded Oligonucleotides

a technology of oligonucleotides and oligonucleotide molecules, which is applied in the direction of transferases, drug compositions, immunological disorders, etc., can solve the problems of difficult to achieve efficient inhibition of gene expression (including protein synthesis) using such compositions, and often subject to nuclease degradation, so as to improve the antisense sequence of prior art and inhibit gene function

Inactive Publication Date: 2009-01-22
LIFE TECH CORP
View PDF99 Cites 60 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, oligonucleotide molecules of the prior art are often subject to nuclease degradation when applied to biological systems.
Therefore, it is often difficult to achieve efficient inhibition of gene expression (including protein synthesis) using such compositions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Double-Stranded Oligonucleotides
  • Double-Stranded Oligonucleotides
  • Double-Stranded Oligonucleotides

Examples

Experimental program
Comparison scheme
Effect test

example 1

Oligonucleotide Compositions Comprising Chimeric Antisense Sequences

[0352]A gapped antisense oligonucleotide comprising 2′-O-methyl RNA arms and an unmodified DNA gap was synthesized. A complementary oligonucleotide was also synthesized using unmodified RNA. A double-stranded duplex was formed and the composition was found to inhibit expression of the target gene.

example 2

Length of Double-Stranded Oligonucleotides and the Presence or Absence of Overhangs has No Effect on Function

[0353]Twenty one and 27-mers were designed to target each of two sites on the p53 molecule (89-90 site, and 93-94 site). The double-stranded molecules were designed with or without 3′-deoxy TT overhangs. The test oligonucleotides were 21-mers with 2 nucleotide 3′ deoxy TT overhangs and without overhangs (blunt ends); and 27-mers with 2 nucleotide 3′ deoxy TT overhangs and without overhangs (blunt ends). Two positive controls were included in the experiment (p53) and two negative controls were also included (FITC).

[0354]A549 cells were transfected with 100 nM of the double-stranded molecules plus 2 ug / mL LIPOFECTAMINE™ 2000. A549 cells were examined 24 hours post-transfection. FITC-labeled molecules were taken up well by cells. Both 21-mers (with or without overhangs) and 27-mers (with or without overhangs) were non-toxic to cells. FIG. 1 shows the result of an experiment comp...

example 3

Activation of the Double-Stranded RNA, Interferon-Inducible Protein Kinase, PKR

[0356]PKR is activated by double-stranded RNA molecules. Active PKR leads to the inhibition of protein synthesis, activation of transcription, and a variety of other cellular effects, including signal transduction, cell differentiation, cell growth inhibition, apoptosis, and antiviral effects. The effect of p53-targeted double-stranded RNA molecules on PKR expression was tested. The level of mRNA was determined using RT-PCR analysis. As shown in FIG. 2, no correlation was observed between the length of the double-stranded oligonucleotide and the level of PKR induction. Accordingly, long oligonucleotides can be used without activating PKR, a marker for interferon induction.

[0357]As illustrated in FIG. 2B, analysis of relative amounts of PKR mRNA after the 21- and 27-mer transfection in HMVEC cells showed approximately a 2 fold increase in PKR mRNA of the siRNA control sequences over no treatment, and appro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

Description

RELATED APPLICATIONS[0001]This application claims the priority of U.S. Provisional Application Nos. 60 / 615,408, filed on Sep. 30, 2004, and 60 / 540,552, filed on Feb. 2, 2004. This application is also a continuation of U.S. Ser. No. 11 / 049,636, filed Feb. 2, 2005 which is a continuation-in-part of U.S. Ser. Nos. 10 / 357,529, filed Feb. 3, 2003, and 10 / 357,826, filed Oct. 2, 2003, both of which claim priority to U.S. Provisional Application 60 / 353,203, filed on Feb. 1, 2002, 60 / 436,238, filed Dec. 23, 2002, 60 / 438,608, filed Jan. 7, 2003, and 60 / 353,381, filed Feb. 1, 2002. The entire contents of the aforementioned applications are hereby expressly incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Complementary oligonucleotide sequences are promising therapeutic agents and useful research tools in elucidating gene function. However, oligonucleotide molecules of the prior art are often subject to nuclease degradation when applied to biological systems. Therefore, it is o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/87C07H21/04C12N15/09A61K31/713A61K48/00A61P1/04A61P9/00A61P17/06A61P27/02A61P29/00A61P31/12A61P31/18A61P31/20A61P35/00A61P37/02A61P43/00C12NC12N15/00C12N15/11C12N15/113
CPCA61K31/713C12N2310/321C12N15/113C12N15/1135C12N15/1137C12N2310/11C12N2310/14C12N2310/315C12N2310/53C12N2320/31C12N2320/50C12N2320/51C12Y207/11022C12Y301/03048C12N15/111A61P1/04A61P9/00A61P17/06A61P27/02A61P29/00A61P31/12A61P31/18A61P31/20A61P35/00A61P37/02A61P43/00C12N13/00C12N2310/33C12N2310/351
Inventor WOOLF, TOD
Owner LIFE TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap